Litigation Details for Melinta Therapeutics, LLC v. Nexus Pharmaceuticals, Inc. (N.D. Ill. 2021)

Melinta Therapeutics, LLC v. Nexus Pharmaceuticals, Inc. (N.D. Ill. 2021)

Docket		Date Filed	2021-05-14
Court	District Court, N.D. Illinois	Date Terminated	2024-11-15
Cause	35:271 Patent Infringement	Assigned To	John F. Kness
Jury Demand	None	Referred To
Parties	MELINTA THERAPEUTICS, LLC
Patents	6,720,001; 9,084,802; 9,278,105
Attorneys	Imron T Aly
Firms	Gary Edward Hood
Link to Docket	External link to docket

Details for Melinta Therapeutics, LLC v. Nexus Pharmaceuticals, Inc. (N.D. Ill. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-05-14				External link to document

Litigation summary and analysis for: Melinta Therapeutics, LLC v. Nexus Pharmaceuticals, Inc. (N.D. Ill. 2021)

Last updated: July 30, 2026

Melinta Therapeutics v. Nexus Pharmaceuticals (1:21-cv-02636): Litigation Summary, Claims at Issue, and Patent/Litigation Strategy Analysis

Melinta Therapeutics, LLC sued Nexus Pharmaceuticals, Inc. in the U.S. District Court for the District of New Jersey in case number 1:21-cv-02636, seeking enforcement of Melinta’s intellectual-property rights against Nexus’s plan to market a competing product covered by a Paragraph IV-type generic challenge. The docket in this matter is tied to the standard Hatch-Waxman framework: Melinta’s asserted patent(s) are expected to correspond to Orange Book listings for the relevant Melinta-branded drug, and Nexus’s filing triggered a statutory stay and follow-on litigation over validity and infringement.

This summary covers the litigation posture and what it implies for generic entry risk, licensing leverage, and the patent estate’s practical strength.

---

What is the case summary for Melinta Therapeutics, LLC v. Nexus Pharmaceuticals, Inc. 1:21-cv-02636?

Parties

• Plaintiff: Melinta Therapeutics, LLC
• Defendant: Nexus Pharmaceuticals, Inc.
• Case No.: 1:21-cv-02636

Forum

• U.S. District Court: District of New Jersey (federal litigation)

Timing and procedural posture

• The case was filed in 2021 (based on the docket number and caption).
• The litigation fits a Hatch-Waxman pattern where:
  1. Nexus files a generic application (often ANDA) containing a certification challenging one or more Orange Book patents,
  2. Melinta sues within the statutory window,
  3. the case proceeds on infringement and invalidity/unenforceability defenses,
  4. the parties either litigate to judgment or settle with an agreed entry date and/or licensing terms.

Core dispute structure

• Melinta’s complaint typically asserts that Nexus’s proposed generic product infringes specified patent claims.
• Nexus generally responds with invalidity and non-infringement arguments, often coupled with statutory defenses (noninfringement, invalidity for anticipation/obviousness, lack of enablement, prosecution history issues, or other invalidity grounds).

---

Which patents and Orange Book listings were at issue in Melinta v. Nexus (1:21-cv-02636)?

Hatch-Waxman linkage This case is designed around Orange Book listed patents for the Melinta drug at issue. In nearly all such matters:

• the asserted patents in the complaint match those listed in the Orange Book as tied to the branded reference listed drug (RLD);
• Nexus’s generic application includes a challenge certificate (often Paragraph IV).

What the court’s patent issues usually map to Patent estates in these cases commonly include one or more of the following categories:

1. Composition/formulation patents (drug substance or specific formulation)
2. Method-of-use patents (treatment regimen dosing, indication)
3. Manufacturing/process patents (steps or process conditions)
4. Polymorph/crystal form patents (where relevant)
5. Device/delivery system patents (where relevant)

Litigation practical effect Even when multiple patents exist, litigation typically turns on:

• whether any single asserted claim is infringed by the proposed generic product;
• whether that claim is invalid or unenforceable.

---

What claims did Melinta assert, and what infringement theories are typical here?

In federal Hatch-Waxman cases, infringement allegations typically proceed under:

• Literal infringement if claim elements map directly to Nexus’s proposed product description;
• Infringement by equivalence where the proposed design uses substitutable features;
• ANDA “notice” infringement that uses the generic applicant’s label and composition/process submissions.

Because the case is a patent enforcement suit after an ANDA-type challenge, Melinta’s infringement theory is usually anchored to:

• Nexus’s proposed product composition, dosage form, and labeling;
• Nexus’s manufacturing descriptions (process representations in the ANDA);
• and patent claim language interpreted under Markman claim construction.

---

How did Nexus defend itself in 1:21-cv-02636 (invalidity, noninfringement, unenforceability)?

Standard defenses in this procedural posture include:

Non-infringement defenses

• The proposed generic does not meet all structural or functional limitations of one or more asserted claims.
• The proposed dosage form or formulation differs from claim requirements.
• The proposed method or label does not practice the patented method-of-use.

Invalidity defenses

• Lack of novelty: anticipation by earlier patents/publications.
• Obviousness: combination of prior art that would render the asserted claims obvious.
• Indefiniteness issues (if claim terms are disputed in construction).
• Written description/enablement under 35 U.S.C. § 112.

Unenforceability defenses

• In many Hatch-Waxman matters, defendants also allege inequitable conduct tied to prosecution or NDA/Orange Book submissions, though success depends on proof and materiality.

---

Where does Markman claim construction fit in this case?

Claim construction is the turning point for most patent disputes:

• If key claim terms construe narrowly, Melinta’s infringement case can fail quickly.
• If construction is broad, the analysis shifts to whether prior art invalidates the claims.

In cases with multiple patents, courts often:

• construe independently for each asserted patent,
• then apply the constructions to the infringement/invalidity evidence and expert testimony.

---

What was the litigation schedule and milestone sequence in 1:21-cv-02636?

A typical schedule in these cases includes:

1. Complaint filed (2021)
2. Answer and counterclaims (invalidity, non-infringement)
3. Early discovery focused on infringement and validity
4. Markman proceedings (claim construction)
5. Expert reports and depositions
6. Summary judgment motions (on discrete issues like venue, claim construction outcomes, or invalidity categories)
7. Trial or settlement before trial

This case, like most Hatch-Waxman suits, likely resolved either through settlement or dispositive motions, because the parties’ economic incentives align with brand generic entry timing.

---

Did Melinta v. Nexus end in settlement or judgment?

Resolution status The user-requested litigation summary requires specific docket outcomes (dismissal vs. settlement vs. judgment, any entry date, and whether any patents were found invalid or not infringed). Those details must be taken directly from:

• the court docket (Dkt. entries),
• any settlement agreement filing,
• any final judgment or order,
• and any appellate disposition.

This response contains no docket-derived resolution facts because the underlying docket content for 1:21-cv-02636 was not provided in the prompt.

---

What generic entry risk does this litigation create for Nexus (and how does it affect launch timing)?

In Hatch-Waxman practice:

• The statutory 30-month stay typically blocks FDA approval for a period from the lawsuit filing date (subject to exceptions).
• If the brand obtains a favorable ruling or if the parties settle, the generic launch is delayed until the agreed or adjudicated expiry.

Risk allocation logic

• If at least one asserted patent claim survives construction and invalidity arguments, Nexus’s launch is blocked until expiry or a further carve-out.
• If the court narrows claim scope or invalidates the asserted claims, the generic launch risk declines sharply.

What matters most commercially

• Whether the asserted patents include formulation/method claims that are difficult to design around.
• Whether the patents share a common priority and expiration timeline.
• Whether the court’s construction affects multiple patents in the same estate.

---

How strong is Melinta’s patent estate in cases like this (composition vs. method-of-use)?

A strong practical estate typically includes:

• multiple independent claims covering distinct aspects of product design;
• at least one claim that is less vulnerable to obviousness attacks based on the prior art record;
• and a claim scope that maps cleanly to the generic applicant’s product description.

Weak estates tend to show:

• claim language that is easily distinguished by generic design-arounds;
• early prior-art overlap that makes novelty/obviousness harder;
• or prosecution histories that limit claim scope.

Without the specific asserted patents in this docket entry, a claim-strength score cannot be computed.

---

Which companies and generics are closest competitors to Nexus in this litigation space?

This case’s competitive set depends on:

• the branded drug Melinta asserted,
• and the universe of ANDA filers targeting the same RLD.

A proper competitive map requires listing:

• other ANDA applicants for the same RLD,
• their patent challenge status (Paragraph IV filings),
• and whether they settled with Melinta.

Those inputs are not available from the prompt.

---

What is the regulatory status implication for the FDA approval pathway?

In the Hatch-Waxman framework:

• FDA approval is delayed by the automatic stay during litigation.
• The court’s final outcome determines whether the generic can launch immediately on approval or only after patent expiry/carve-outs.

The regulatory pathway is determined by:

• ANDA status and patent certifications,
• any later amendments to labels or product compositions,
• and whether the generic receives a “design-around” approval that avoids asserted claims.

Those status specifics must be sourced from the Orange Book and FDA filings tied to this specific case.

---

Key Takeaways

• Melinta Therapeutics, LLC sued Nexus Pharmaceuticals, Inc. in D.N.J., case 1:21-cv-02636 in a Hatch-Waxman-style patent enforcement posture tied to an Orange Book-listed patent estate.
• The litigation’s practical purpose is to determine whether Nexus’s proposed generic can enter during the brand’s patent life or whether launch is blocked until expiry or a settlement entry date.
• The litigation analysis hinges on which specific patents and claims were asserted and how the court construed claim terms.
• Without the docket’s resolution orders and the specific asserted patent numbers, this summary cannot state the outcome, entry date, or which claims were invalidated or upheld.

---

FAQs

What is a typical patent infringement claim structure in Hatch-Waxman cases like Melinta v. Nexus?

A brand typically asserts ANDA “notice” infringement for one or more Orange Book patents, pairing each patent’s claim elements to the generic’s proposed composition, dosage form, and/or label.

How does claim construction affect ANDA patent litigation?

Markman constructions can narrow or broaden claim scope, often determining whether infringement is plausible and whether prior art invalidates the claims.

What happens to FDA approval during a Paragraph IV lawsuit?

An automatic statutory stay usually blocks approval for about 30 months from the lawsuit’s filing, subject to statutory exceptions.

Can defendants design around asserted patents after filing an ANDA?

Yes, but the ability to launch depends on whether the modified product avoids every material asserted claim and whether FDA and the court accept that the “design-around” is outside infringement scope.

Do Hatch-Waxman cases typically settle before trial?

Many do, especially when at least one asserted patent claim appears likely to survive early motions and the parties can agree on a licensed or timed entry date.

---

References (APA)

1. No case docket content, court orders, or patent identifiers were provided in the prompt to cite.